SEC Company Response from IGC Pharma, Inc. (IGC) (CIK 0001326205) (IGC) — Feb 24, 2014
IGC Pharma, Inc. (IGC) (CIK 0001326205)
Date: Feb. 24, 2014 · CIK: 0001326205 · Accession: 0001185185-14-000407
AI Filing Summary & Sentiment
Reasoning
Letter
VIA EDGAR Securities and Exchange Commission Office of Beverages, Apparel and Mining Form 10-K for the Year Ended March 31, 2013 Filed July 16, 2013 Form 8-K Filed July 1, 2013 File No. 1-32830
Dear Ms. Jenkins:
On Friday February 21, 2014 we spoke with Assistant Chief Accountant Ms. Nasreen Mohammed, and we were granted an extension of ten more business days for the filing of our response to the referenced comments.
We are very grateful for the Staff’s guidance, discussions over the phone, and understanding of our situation. We will file our response by March 10, 2014.
Sincerely,
ss:
Show Raw Text
CORRESP
1
filename1.htm
indiaglobal-corresp022414.htm
India Globalization Capital, Inc.
4336 Montgomery Avenue
Bethesda, Maryland 20814
Phone: 301-983-0998
Fax: 240-465-0273
February 24, 2014
VIA EDGAR
Securities and Exchange Commission
100 F. Street, N.E.
Washington, D.C. 20549
Attn: Ms. Tia Jenkins
Senior Assistant Chief Accountant
Office of Beverages, Apparel and Mining
Re:
India Globalization Capital, Inc.
Form 10-K for the Year Ended
March 31, 2013 Filed July 16, 2013
Form 8-K Filed July 1, 2013
File No. 1-32830
Dear Ms. Jenkins:
On Friday February 21, 2014 we spoke with Assistant Chief Accountant Ms. Nasreen Mohammed, and we were granted an extension of ten more business days for the filing of our response to the referenced comments.
We are very grateful for the Staff’s guidance, discussions over the phone, and understanding of our situation. We will file our response by March 10, 2014.
Sincerely,
ss:
India Globalization Capital, Inc.
Ram Mukunda,
Chief Executive Office